These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26138438)

  • 1. The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease.
    Jost WH
    J Neural Transm (Vienna); 2016 Jan; 123(1):51-5. PubMed ID: 26138438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drooling in Parkinson's disease: A randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins.
    Narayanaswami P; Geisbush T; Tarulli A; Raynor E; Gautam S; Tarsy D; Gronseth G
    Parkinsonism Relat Disord; 2016 Sep; 30():73-7. PubMed ID: 27406786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    J Neurol; 2009 Apr; 256(4):563-7. PubMed ID: 19401804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease.
    Ondo WG; Hunter C; Moore W
    Neurology; 2004 Jan; 62(1):37-40. PubMed ID: 14718694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin.
    Egevad G; Petkova VY; Vilholm OJ
    J Parkinsons Dis; 2014; 4(3):321-6. PubMed ID: 24919823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin injections for children with excessive drooling.
    Hassin-Baer S; Scheuer E; Buchman AS; Jacobson I; Ben-Zeev B
    J Child Neurol; 2005 Feb; 20(2):120-3. PubMed ID: 15794177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
    Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
    Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B.
    Wilken B; Aslami B; Backes H
    Neuropediatrics; 2008 Aug; 39(4):200-4. PubMed ID: 19165707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative reduction of saliva production with botulinum toxin type B injection into the salivary glands.
    Turk-Gonzales M; Odderson IR
    Neurorehabil Neural Repair; 2005 Mar; 19(1):58-61. PubMed ID: 15673844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does botulinum toxin decrease frequency and severity of sialorrhea in Parkinson's disease?
    Nóbrega AC; Rodrigues B; Torres AC; Enzo A; Melo A
    J Neurol Sci; 2007 Feb; 253(1-2):85-7. PubMed ID: 17229441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of intraglandular injections of Botulinum toxin for the treatment of sialorrhea in children with cerebral palsy: a review.
    Porte M; Chaléat-Valayer E; Patte K; D'Anjou MC; Boulay C; Laffont I
    Eur J Paediatr Neurol; 2014 Nov; 18(6):649-57. PubMed ID: 24931915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasound-Guided Botulinum Toxin Injections into the Salivary Glands for the Treatment of Drooling.
    Abboud WA; Nadel S; Hassin-Baer S; Arad A; Dobriyan A; Yahalom R
    Isr Med Assoc J; 2019 Feb; 21(2):116-119. PubMed ID: 30772963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
    Mancini F; Zangaglia R; Cristina S; Sommaruga MG; Martignoni E; Nappi G; Pacchetti C
    Mov Disord; 2003 Jun; 18(6):685-8. PubMed ID: 12784273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What could predict effectiveness of Botulinum Toxin to treat drooling: a search for evidence of discriminatory factors on the level of body functions or structures.
    Erasmus CE; van Hulst K; Scheffer AR; van Limbeek J; van den Hoogen FJ; Rotteveel JJ; Jongerius PH
    Eur J Paediatr Neurol; 2012 Mar; 16(2):126-31. PubMed ID: 21783393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum Toxin Therapy for Parkinson's Disease.
    Wagle Shukla A; Malaty IA
    Semin Neurol; 2017 Apr; 37(2):193-204. PubMed ID: 28511260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sialorrhea in Parkinson's Disease.
    Isaacson J; Patel S; Torres-Yaghi Y; Pagán F
    Toxins (Basel); 2020 Oct; 12(11):. PubMed ID: 33142833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G; Millevolte M; Capecci M; Provinciali L; Ceravolo MG
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drooling in Parkinson's disease: a novel speech and language therapy intervention.
    Marks L; Turner K; O'Sullivan J; Deighton B; Lees A
    Int J Lang Commun Disord; 2001; 36 Suppl():282-7. PubMed ID: 11340797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A.
    Tiigimäe-Saar J; Tamme T; Rosenthal M; Kadastik-Eerme L; Taba P
    Neurol Sci; 2018 May; 39(5):871-877. PubMed ID: 29460161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease.
    Contarino MF; Pompili M; Tittoto P; Vanacore N; Sabatelli M; Cedrone A; Rapaccini GL; Gasbarrini G; Tonali PA; Bentivoglio AR
    Parkinsonism Relat Disord; 2007 Jul; 13(5):299-303. PubMed ID: 16807056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.